Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: EPA:SAN
- CUSIP: N/A
- Web: en.sanofi.com
Average Prices:- 50 Day Moving Avg: €25.48
- 200 Day Moving Avg: €25.74
P/E:- Trailing P/E Ratio: 11.47
- P/E Growth: 2.25
Dividend:
Frequently Asked Questions for Sanofi SA (EPA:SAN)
What is Sanofi SA's stock symbol?
Sanofi SA trades on the EPA under the ticker symbol "SAN."
Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?
16 brokerages have issued 12-month target prices for Sanofi SA's stock. Their forecasts range from €75.00 to €100.00. On average, they anticipate Sanofi SA's stock price to reach €88.00 in the next year. View Analyst Ratings for Sanofi SA.
Who are some of Sanofi SA's key competitors?
Some companies that are related to Sanofi SA include Accor SA (AC), Air France KLM SA (AF), Air Liquide SA (AI), Airbus SE (EAD), Airbus SE (AIR), Alcatel Lucent SA (ALU), Alstom SA (ALO), Axa SA (CS), BNP Paribas SA (BNP), Bouygues SA (EN), Capgemini SE (CAP), Carrefour SA (CA), Cie Gnrl des Etblsmnts Michelin SCA (ML), Danone SA (BN), Electricite de France SA (EDF), Engie SA (GSZ), Essilor International SA (EI) and JCDecaux SA (DEC).
Who are Sanofi SA's key executives?
Sanofi SA's management team includes the folowing people:
- Serge Weinberg, Independent Chairman of the Board
- Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
- Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
- Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
- Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
- Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
- Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
- David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
- David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
- Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team
MarketBeat Community Rating for Sanofi SA (EPA SAN)MarketBeat's community ratings are surveys of what our community members think about Sanofi SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Sanofi SA (EPA:SAN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 9 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.19) |
| Consensus Price Target: | €88.00 |
Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 8/7/2017 | Goldman Sachs Group, Inc. (The) | Set Price Target | Neutral | €82.00 |  |
| 8/1/2017 | Deutsche Bank AG | Set Price Target | Buy | €96.00 | |
| 8/1/2017 | J P Morgan Chase & Co | Set Price Target | Neutral | €90.00 | |
| 7/31/2017 | Sanford C. Bernstein | Set Price Target | Neutral | €90.00 | |
| 7/31/2017 | Berenberg Bank | Set Price Target | Neutral | €97.00 | |
| 7/31/2017 | S&P Global | Set Price Target | Neutral | €90.00 | |
| 7/26/2017 | Kepler Capital Markets | Set Price Target | Buy | €89.00 | |
| 7/4/2017 | Credit Suisse Group | Set Price Target | Buy | €95.00 | |
| 6/16/2017 | Jefferies Group LLC | Set Price Target | Neutral | €90.00 | |
| 6/6/2017 | Morgan Stanley | Set Price Target | Buy | €91.00 | |
| 5/8/2017 | Barclays PLC | Set Price Target | Sell | €75.00 | |
| 4/7/2017 | HSBC Holdings plc | Set Price Target | Sell | €77.00 | |
| 3/23/2017 | Societe Generale | Set Price Target | Buy | €100.00 | |
| 1/6/2017 | Citigroup Inc. | Reiterated Rating | Neutral | | |
| 12/6/2016 | S&P Global Inc. | Set Price Target | Neutral | €80.00 | |
| 9/14/2016 | BNP Paribas | Set Price Target | Neutral | €78.00 | |
| 6/30/2016 | Independent Research GmbH | Set Price Target | Neutral | €77.00 | |
| 6/9/2016 | Baader Bank | Set Price Target | Neutral | €78.00 | |
| 2/9/2016 | S&P Equity Research | Set Price Target | Buy | €85.00 | |
(Data available from 8/23/2015 forward)
Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Sanofi SA (EPA:SAN)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)
| Source: |
|
| Date | Headline |
|---|
 | Performance of Sanofi’s Established Products in 2Q17
finance.yahoo.com - August 19 at 7:15 AM |
| Sanofi’s General Medicines and Consumer Healthcare in 2Q17
finance.yahoo.com - August 19 at 7:15 AM |
| A Look at Sanofi Pasteur’s Performance in 2Q17
finance.yahoo.com - August 19 at 7:15 AM |
 | Where Does Zika Virus Vaccine Research Stand Now? - Benzinga
www.benzinga.com - August 14 at 3:00 AM |
 | Mexico watchdog finds big pharma faces no competition on some ... - Reuters
www.reuters.com - August 10 at 7:39 AM |
 | CVS Health's dull third-quarter forecast overshadows profit beat - Business Insider
www.businessinsider.com - August 9 at 7:09 AM |
| Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
finance.yahoo.com - August 9 at 7:09 AM |
 | Goldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (SAN) a €82.00 Price Target
www.americanbankingnews.com - August 7 at 9:20 PM |
| This Week's Pharma, Energy IPOs - Benzinga
www.benzinga.com - August 7 at 3:18 PM |
| Sanofi SA (SAN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 4 at 10:44 AM |
| Regeneron beats profit view, to end antibody deal with Sanofi - Reuters
www.reuters.com - August 4 at 7:51 AM |
| Regeneron quarterly profit nearly doubles
finance.yahoo.com - August 4 at 7:51 AM |
| Regeneron: Wait, I Thought It Was Good News?!?!
finance.yahoo.com - August 4 at 7:51 AM |
 | Europe ETF (EZU) Hits New 52-Week High - Nasdaq
www.nasdaq.com - August 2 at 10:30 PM |
 | Sanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook - TheStreet.com
www.thestreet.com - August 2 at 7:28 AM |
| Deutsche Bank AG Reiterates "€96.00" Price Target for Sanofi SA (EPA:SAN)
www.americanbankingnews.com - August 1 at 12:56 PM |
 | Sanofi (SNY) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 1 at 6:10 AM |
 | Sanofi Q2 Profit Down, Sales Rise; Lifts FY17 Earnings View; Stock Up
www.rttnews.com - August 1 at 6:10 AM |
| Biotech Is Only Expensive When You Follow the Crowd
finance.yahoo.com - August 1 at 6:10 AM |
| Praluent Could Witness Steady Growth in 2017
finance.yahoo.com - August 1 at 6:10 AM |
| Edited Transcript of SAN.PA earnings conference call or presentation 31-Jul-17 12:30pm GMT
finance.yahoo.com - August 1 at 6:10 AM |
| Sanofi meets 2Q profit forecasts
finance.yahoo.com - August 1 at 6:10 AM |
| Sanofi SA (SAN) Given a €97.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - July 31 at 12:21 PM |
| Sanford C. Bernstein Analysts Give Sanofi SA (EPA:SAN) a €90.00 Price Target
www.americanbankingnews.com - July 31 at 11:11 AM |
| Sanofi Q2 Profit Declines, Sales Rise; Lifts FY17 Business EPS View - Nasdaq
www.nasdaq.com - July 31 at 2:30 AM |
| Sanofi Raises FY 2017 Business EPS(1) Guidance to Broadly Stable at CER(2)
finance.yahoo.com - July 31 at 2:30 AM |
| Green River (City of) WY, Variable Rate Demand Revenue Bonds (Rhone-Poulenc of Wyoming, L.P. Project), Series 1994, $11.4MM -- Moody's Affirms A1/VMIG 1 on Green River, WY's LOC-backed VRDBs (Rhone-Poulenc of WY, L.P.) Series 1994
finance.yahoo.com - July 28 at 7:35 AM |
| Sanofi SA (EPA:SAN) Given a €82.00 Price Target at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - July 26 at 9:38 AM |
| UPDATE 1-US jury sides with Amphastar over Momenta in drug patent trial - Business Insider
www.businessinsider.com - July 22 at 8:30 AM |
| FDA tentatively approves Merck's copycat of Sanofi's Lantus - Reuters
www.reuters.com - July 21 at 6:52 AM |
| Sanofi SA (SAN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 20 at 10:53 AM |
 | Road to Brexit: The Heartlands Where a Good Deal Matters Most - Bloomberg
www.bloomberg.com - July 13 at 9:08 AM |
| Sanofi: Pre-quarterly Results Communication
finance.yahoo.com - July 13 at 9:08 AM |
| Sanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed
www.reuters.com - July 12 at 7:42 AM |
| Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences - TheStreet.com
www.thestreet.com - July 12 at 7:42 AM |
| Sanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed - Reuters
www.reuters.com - July 12 at 7:42 AM |
 | Chronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 7:23 AM |
 | Sanofi to buy vaccine maker Protein Sciences - MarketWatch
www.marketwatch.com - July 11 at 7:23 AM |
| European stocks stuck in tight ranges as traders wait for Yellen
finance.yahoo.com - July 11 at 7:23 AM |
| Sanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 10 at 11:14 AM |
| Alnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why
finance.yahoo.com - July 7 at 9:42 AM |
| Pfizer receives token payment to exit Brazil venture, sources say ... - Reuters
www.reuters.com - July 6 at 8:46 AM |
| Pfizer receives token payment to exit Brazil venture, sources say - Business Insider
www.businessinsider.com - July 5 at 10:20 AM |
| Credit Suisse Group Analysts Give Sanofi SA (SAN) a €95.00 Price Target
www.americanbankingnews.com - July 4 at 7:25 AM |
| Buoyant Europe Stocks Turn Out to Be `Pain Trade' of First Half - Bloomberg
www.bloomberg.com - July 1 at 7:12 AM |
| IMF Lowers US Growth Outlook: International ETFs to Buy - Nasdaq
www.nasdaq.com - June 29 at 6:43 AM |
| Domino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move - Bloomberg
www.bloomberg.com - June 27 at 8:02 AM |
| Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union
finance.yahoo.com - June 27 at 8:02 AM |
| Good Companies From Warren Buffett's Portfolio
finance.yahoo.com - June 25 at 8:07 PM |
| Good Companies From Warren Buffett's Portfolio - Nasdaq.com - Nasdaq
www.nasdaq.com - June 25 at 5:33 AM |
